||Neonatal Drug Therapy Manual
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
- Adjunctive treatment for BPD
- Metered-dose inhaler, use with aerochamber
- 1 - 2 puffs (125 - 250 mcg) BID
- GI: dry mouth, oral candidiasis
- Respiratory: bronchospasm, cough, hoarseness
As fluticasone has an extremely low oral bioavailability (<1%), systemic effects are minimal
Reconstitution and Stability:
- If salbutamol or ipratropium is also ordered, give salbutamol or ipratropium first, wait 5 minutes and then administer fluticasone
- After each administration, rinse mouth
-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 9th-11th Editions. Hudson: Lexi-Comp Inc.; 2002-2004.
-Young TE, Mangum B. Neofax(R).13th-16th Editions. Raleigh: Acorn Publishing; 2000-2003.
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.